ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Regulatory Considerations for Biosimilars Development in the U.S. "
Episode Synopsis
The development of biosimilar products in the US has been progressing since the regulatory pathway was established as part of the Affordable Care Act. Listen as members of Veristat’s Regulatory team delve into the analytical and clinical science of biosimilars and their regulatory pathway.
More episodes of the podcast Advancing Revolutionary Therapies
CMC Pitfalls: From Benchtop to IND
31/10/2022
Emergency Use Authorizations
22/09/2022
Orphan Drug Designations and Orphan Subsets
11/09/2022
Season 3 Trailer
26/08/2022
In God we trust